Wall Street brokerages predict that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will announce $4.65 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Regeneron Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $3.69 and the highest estimate coming in at $5.13. Regeneron Pharmaceuticals posted earnings per share of $3.04 during the same quarter last year, which suggests a positive year-over-year growth rate of 53%. The company is scheduled to report its next quarterly earnings report on Thursday, February 8th.

On average, analysts expect that Regeneron Pharmaceuticals will report full year earnings of $15.76 per share for the current financial year, with EPS estimates ranging from $13.99 to $16.63. For the next year, analysts expect that the business will report earnings of $16.77 per share, with EPS estimates ranging from $13.79 to $19.06. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The firm had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm’s revenue for the quarter was up 23.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.13 EPS.

Several research firms recently issued reports on REGN. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 31st. Evercore ISI reduced their price objective on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a research note on Thursday, November 16th. Barclays lowered shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and reduced their price objective for the company from $450.00 to $395.00 in a research note on Friday, October 20th. Guggenheim reaffirmed a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $490.00 price objective (up previously from $450.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, October 6th. Two research analysts have rated the stock with a sell rating, seventeen have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $465.40.

In other news, Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the transaction, the director now owns 11,000 shares in the company, valued at $4,950,000. The disclosure for this sale can be found here. Company insiders own 10.80% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Dupont Capital Management Corp purchased a new position in Regeneron Pharmaceuticals in the second quarter worth about $220,000. Gamco Investors INC. ET AL acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at about $242,000. Blair William & Co. IL lifted its position in shares of Regeneron Pharmaceuticals by 4.8% during the second quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock worth $841,000 after purchasing an additional 79 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Regeneron Pharmaceuticals by 11.1% during the second quarter. Victory Capital Management Inc. now owns 3,962 shares of the biopharmaceutical company’s stock worth $1,946,000 after purchasing an additional 395 shares during the last quarter. Finally, Andra AP fonden lifted its position in shares of Regeneron Pharmaceuticals by 11.1% during the second quarter. Andra AP fonden now owns 1,000 shares of the biopharmaceutical company’s stock worth $491,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 66.63% of the company’s stock.

Regeneron Pharmaceuticals (NASDAQ REGN) opened at $384.09 on Thursday. The stock has a market capitalization of $41,630.00, a PE ratio of 34.89, a P/E/G ratio of 1.50 and a beta of 1.53. Regeneron Pharmaceuticals has a 52-week low of $340.09 and a 52-week high of $543.55. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07.

TRADEMARK VIOLATION WARNING: This report was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://theolympiareport.com/2017/12/28/4-65-earnings-per-share-expected-for-regeneron-pharmaceuticals-inc-regn-this-quarter.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.